105 related articles for article (PubMed ID: 7891627)
1. On the determination of the effective transmission factor for stainless steel ovoid shielding segments and estimation of their shielding efficacy for the clinical situation.
Verellen D; De Neve W; Van den Heuvel F; Storme G; Coen V; Coghe M
Med Phys; 1994 Nov; 21(11):1677-84. PubMed ID: 7891627
[TBL] [Abstract][Full Text] [Related]
2. A monte carlo dosimetry study of vaginal 192Ir brachytherapy applications with a shielded cylindrical applicator set.
Lymperopoulou G; Pantelis E; Papagiannis P; Rozaki-Mavrouli H; Sakelliou L; Baltas D; Karaiskos P
Med Phys; 2004 Nov; 31(11):3080-6. PubMed ID: 15587661
[TBL] [Abstract][Full Text] [Related]
3. Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
Krishnamurthy D; Weinberg V; Cunha JA; Hsu IC; Pouliot J
Brachytherapy; 2011; 10(6):461-5. PubMed ID: 21397569
[TBL] [Abstract][Full Text] [Related]
4. Fetal dose measurements and shielding efficiency assessment in a custom setup of (192)Ir brachytherapy for a pregnant woman with breast cancer.
Candela-Juan C; Gimeno-Olmos J; Pujades MC; Rivard MJ; Carmona V; Lliso F; Celada F; RamÃrez-Coves JL; Ballester F; Tormo A; Perez-Calatayud J
Phys Med; 2015 May; 31(3):286-92. PubMed ID: 25681030
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of rectal shielding in a Henschke system applicator.
Howlett SJ; Denham JW; Kron T
Strahlenther Onkol; 1996 May; 172(5):265-9. PubMed ID: 8633259
[TBL] [Abstract][Full Text] [Related]
6. Measurement and calculation of heterogeneity correction factors for an Ir-192 high dose-rate brachytherapy source behind tungsten alloy and steel shields.
Kirov AS; Williamson JF; Meigooni AS; Zhu Y
Med Phys; 1996 Jun; 23(6):911-9. PubMed ID: 8798161
[TBL] [Abstract][Full Text] [Related]
7. Screens in ovoids of a Selectron cervix applicator.
Meertens H; van der Laarse R
Radiother Oncol; 1985 Jan; 3(1):69-80. PubMed ID: 3975442
[TBL] [Abstract][Full Text] [Related]
8. Study of encapsulated 170Tm sources for their potential use in brachytherapy.
Ballester F; Granero D; Perez-Calatayud J; Venselaar JL; Rivard MJ
Med Phys; 2010 Apr; 37(4):1629-37. PubMed ID: 20443484
[TBL] [Abstract][Full Text] [Related]
9. Comparison of radiation shielding requirements for HDR brachytherapy using 169Yb and 192Ir sources.
Lymperopoulou G; Papagiannis P; Sakelliou L; Georgiou E; Hourdakis CJ; Baltas D
Med Phys; 2006 Jul; 33(7):2541-7. PubMed ID: 16898458
[TBL] [Abstract][Full Text] [Related]
10. Monte Carlo dose calculations for a new ovoid shield system for carcinoma of the uterine cervix.
Weeks KJ
Med Phys; 1998 Dec; 25(12):2288-92. PubMed ID: 9874820
[TBL] [Abstract][Full Text] [Related]
11. A dosimetric comparison of 169Yb versus 192Ir for HDR prostate brachytherapy.
Lymperopoulou G; Papagiannis P; Sakelliou L; Milickovic N; Giannouli S; Baltas D
Med Phys; 2005 Dec; 32(12):3832-42. PubMed ID: 16475783
[TBL] [Abstract][Full Text] [Related]
12. Monte Carlo model for a prototype CT-compatible, anatomically adaptive, shielded intracavitary brachytherapy applicator for the treatment of cervical cancer.
Price MJ; Gifford KA; Horton JL; Eifel PJ; Gillin MT; Lawyer AA; Mourtada F
Med Phys; 2009 Sep; 36(9):4147-55. PubMed ID: 19810488
[TBL] [Abstract][Full Text] [Related]
13. Development of prototype shielded cervical intracavitary brachytherapy applicators compatible with CT and MR imaging.
Price MJ; Jackson EF; Gifford KA; Eifel PJ; Mourtada F
Med Phys; 2009 Dec; 36(12):5515-24. PubMed ID: 20095264
[TBL] [Abstract][Full Text] [Related]
14. Using measured dose distribution data of the Fletcher-Suit-Delclos colpostat in brachytherapy treatment planning.
Yorke ED; Schell MC; Gaskill JW; Ling CC
Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1413-9. PubMed ID: 3624050
[TBL] [Abstract][Full Text] [Related]
15. Direct reconstruction and associated uncertainties of 192Ir source dwell positions in ring applicators using gafchromic film in the treatment planning of HDR brachytherapy cervix patients.
Awunor OA; Dixon B; Walker C
Phys Med Biol; 2013 May; 58(10):3207-25. PubMed ID: 23603854
[TBL] [Abstract][Full Text] [Related]
16. Exploring the potential of mixed-source brachytherapy for the treatment of cervical cancer using high-dose rate 192Ir and/or 50 kV electronic sources.
Cohen DM; Hiatt JR; O'Connor B; Curran B; Sternick ES; Wazer DE
Brachytherapy; 2011; 10(2):141-6. PubMed ID: 20889390
[TBL] [Abstract][Full Text] [Related]
17. Accuracy assessment of the superposition principle for evaluating dose distributions of elongated and curved 103Pd and 192Ir brachytherapy sources.
Bannon EA; Yang Y; Rivard MJ
Med Phys; 2011 Jun; 38(6):2957-63. PubMed ID: 21815369
[TBL] [Abstract][Full Text] [Related]
18. HDR brachytherapy of rectal cancer using a novel grooved-shielding applicator design.
Webster MJ; Devic S; Vuong T; Han DY; Scanderbeg D; Choi D; Song B; Song WY
Med Phys; 2013 Sep; 40(9):091704. PubMed ID: 24007137
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of intracavitary applicators in 192Ir-HDR brachytherapy.
Ye SJ; Brezovich IA; Shen S; Duan J; Popple RA; Pareek PN
Med Phys; 2004 Jul; 31(7):2097-106. PubMed ID: 15305463
[TBL] [Abstract][Full Text] [Related]
20. Monte Carlo dosimetry of the microselectron HDR 192Ir brachytherapy source using MCNP4A.
Wallace S; Wong T; Fernando W
Australas Phys Eng Sci Med; 1998 Mar; 21(1):11-7. PubMed ID: 9633148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
